Syndax Pharmaceuticals Inc SNDX

Rank #2248 · Nasdaq · $1.2B market cap

Audited by Deloitte & Touche LLP, no going-concern flag in the latest filing.

Score

27.4

P/E

-5.8

P/B

2.59

ROE

-44.8%

Op. Margin

–%

Debt Ratio

93%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆

Weak

P/E -5.8x, P/B 2.59x. Ranks in the top 67% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -44.8%. Ranks in the top 87% of the universe.

Safety ★★★☆☆

Good

Debt ratio 93%. Ranks in the top 37% of the universe.

Growth –

No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Profitability is the relative weakness (relative to this universe).

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2016	–	$-0.0B	$-0.0B	$-0.1B	–	-18
2017	–	$-0.0B	$-0.0B	$-0.2B	–	-16
2018	$0.0B	$-0.0B	$-0.0B	$-0.3B	-3587.4	-13
2019	$0.0B	$-0.1B	$-0.1B	$0.1B	-2939.0	37
2020	$0.0B	$-0.1B	$-0.1B	$0.1B	-5001.7	31
2021	$0.0B	$-0.1B	$-0.1B	$0.1B	-3792.9	91
2022	$0.0B	$-0.1B	$-0.1B	$0.0B	-4708.2	131
2023	$0.1B	$0.0B	$0.0B	$0.3B	18.8	12
2024	$0.0B	$-0.2B	$-0.1B	$0.4B	–	14
2025	$0.0B	$-0.2B	$-0.2B	$0.5B	–	93